Endocrine Treatment for Breast Cancer Patients Revisited—History, Standard of Care, and Possibilities of Improvement
Purpose of review: Due to the findings of current studies and the approval of novel substances for the therapy of hormone-receptor-positive breast cancer patients, the established standards of endocrine treatment are changing. The purpose of this review is to give an overview of the history of endoc...
Guardado en:
Autores principales: | Naiba Nabieva, Peter A. Fasching |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
MDPI AG
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/b2660c6df8e646dcb828390fda321e7e |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Cost-effectiveness of Tamoxifen, Aromatase Inhibitor, and Switch Therapy (Adjuvant Endocrine Therapy) for Breast Cancer in Hormone Receptor Positive Postmenopausal Women in India
por: Butani D, et al.
Publicado: (2021) -
Association of Endocrine Therapy and Dementia in Women with Breast Cancer
por: Thompson MR, et al.
Publicado: (2021) -
Dietary Supplement Use and Interactions with Tamoxifen and Aromatase Inhibitors in Breast Cancer Survivors Enrolled in Lifestyle Interventions
por: Maura Harrigan, et al.
Publicado: (2021) -
The Role of CDK4 in the Pathogenesis of Pancreatic Cancer
por: Emily Jiggens, et al.
Publicado: (2021) -
Resistance Mechanisms to Combined CDK4/6 Inhibitors and Endocrine Therapy in ER+/HER2− Advanced Breast Cancer: Biomarkers and Potential Novel Treatment Strategies
por: Abeer J. Al-Qasem, et al.
Publicado: (2021)